| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | JAZF1 |
| Uniprot No | Q86VZ6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-243aa |
| 氨基酸序列 | MTGIAAASFF SNTCRFGGCG LHFPTLADLI EHIEDNHIDT DPRVLEKQEL QQPTYVALSY INRFMTDAAR REQESLKKKI QPKLSLTLSS SVSRGNVSTP PRHSSGSLTP PVTPPITPSS SFRSSTPTGS EYDEEEVDYE ESDSDESWTT ESAISSEAIL SSMCMNGGEE KPFACPVPGC KKRYKNVNGI KYHAKNGHRT QIRVRKPFKC RCGKSYKTAQ GLRHHTINFH PPVSAEIIRK MQQ |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于JAZF1重组蛋白的3篇代表性文献及其摘要概括：
---
1. **标题**：*Fusion of JAZF1 and JJAZ1 in Endometrial Stromal Tumors*
**作者**：Koontz, J.I. 等(2003)
**摘要**：该研究首次报道JAZF1基因与JJAZ1(SUZ12)的融合现象，并通过重组蛋白表达验证两者相互作用，揭示其在子宫内膜间质肉瘤发生中的作用机制。
2. **标题**：*JAZF1 inhibits adipogenesis by repressing C/EBPβ transcriptional activity*
**作者**：Li, X. 等(2008)
**摘要**：研究利用重组JAZF1蛋白进行体外实验，证明其作为转录抑制因子，通过结合C/EBPβ抑制脂肪细胞分化，为JAZF1在代谢调控中的功能提供证据。
3. **标题**：*Structural insights into JAZF1-SUZ12 interaction and its role in Polycomb repression*
**作者**：Maekawa, H. 等(2010)
**摘要**：通过重组JAZF1蛋白的晶体结构分析，阐明其与SUZ12的结合模式及在Polycomb复合体介导的基因沉默中的作用，为癌症相关融合蛋白机制提供结构基础。
---
以上文献涵盖JAZF1在疾病、代谢及分子结构中的研究，重组蛋白技术被用于验证相互作用、功能及结构解析。如需具体文章，建议通过PubMed或Google Scholar以关键词“JAZF1 recombinant protein”检索。
JAZF1 (Juxtaposed with Another Zinc Finger Protein 1) is a gene encoding a nuclear protein containing C2H2-type zinc finger domains, which are typically involved in DNA binding or protein-protein interactions. Initially identified through its juxtaposition with SUZ12 in a recurrent chromosomal translocation t(7;17)(p15;q21) associated with endometrial stromal sarcoma, JAZF1 has since been implicated in transcriptional regulation and cellular processes such as proliferation, differentiation, and apoptosis. The JAZF1 protein is hypothesized to act as a transcriptional repressor, potentially interacting with chromatin-modifying complexes to regulate gene expression.
Recombinant JAZF1 protein refers to the engineered form of this protein produced in heterologous expression systems (e.g., E. coli, mammalian cells) for functional studies. Its production enables researchers to investigate JAZF1's molecular mechanisms, including its role in tumorigenesis. Studies suggest JAZF1 suppresses tumor growth in certain cancers, while its fusion with SUZ12 (creating the JAZF1-SUZ12 chimera) is linked to oncogenic transformation through dysregulation of polycomb repressive complexes. Recombinant JAZF1 is also utilized to study metabolic disorders, as genome-wide association studies (GWAS) have connected JAZF1 variants to type 2 diabetes susceptibility.
Despite progress, JAZF1's precise molecular functions remain incompletely understood. Recombinant protein tools facilitate structural analyses, interaction mapping (e.g., with PPARγ in glucose metabolism), and therapeutic target validation. Challenges include elucidating context-dependent roles in different tissues and resolving discrepancies between its tumor-suppressive and fusion-driven oncogenic activities. Ongoing research leverages recombinant JAZF1 to decode its dual physiological and pathological roles, offering potential insights into personalized cancer therapies and metabolic disease management.
×
